Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

BackgroundThere is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.MethodsIn this exploratory, observational study, we recruited 28 pati...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ryan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, Yuan Hao, Samantha Nyovanie, Andrea Lopez, David Mieles, Courtney Ng, Katherine Perdomo, Nicole Scott, James B. Lewin, Robin L. Avila, Jen Smrtka, Yury Patskovsky, Jonathan Howard, Gregg J. Silverman, Michelle Krogsgaard
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-11-01
Rangatū:	Frontiers in Immunology
Ngā marau:	multiple sclerosis (MS) T cell B cell SARS-CoV-2 COVID-19 natalizumab (Tysabri)
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568157/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!